AMRX.N News & Events

Reports Q1 revenue $723M, consensus $720.52M. "Amneal delivered a very strong start to 2026, reflecting the strength of our diversified business and multiple growth drivers across the portfolio. Our Specialty business continues to perform exceptionally well, led by CREXONT and the recent launch of BREKIYA autoinjector, alongside a strong cadence of key launches in Affordable Medicines. We are entering the Kashiv transaction from a position of strength, at a time when we see an extended period of accelerated growth ahead with no shortage of opportunities across our core businesses. Combined with our very strong Q1 results, we are pleased to increase our FY26 guidance," said Chirag and Chintu Patel, Co-Founders and Co-CEO of Amneal.

Amneal Pharmaceuticals announced that it has entered into a definitive agreement to acquire 100% of Kashiv BioSciences, in a transaction with consideration that includes $375M of cash and $375M of equity payable at closing, plus up to $350M in potential payments based on the achievement of certain regulatory milestones, potential royalties based on commercial milestones, and funding of operations through closing. Kashiv is among a select group of U.S.-based companies with proven end-to-end biosimilars capabilities across development and manufacturing, and a robust pipeline. This transaction will establish a scaled, fully integrated global biosimilars platform at a pivotal moment, ahead of a more than $300B projected global biologics loss-of-exclusivity wave over the next decade, accelerating growth and meaningfully extending and diversifying Amneal's long-term growth profile. The transaction is subject to approval by Amneal shareholders, receipt of regulatory approvals and satisfaction of customary closing conditions, and is expected to close in the second half of 2026.

Raises FY26 revenue to $3.05B-$3.15B from $3.05B-$3.15B. Consensus is for FY26 EPS 99c and for revenue $3.1B. Reaffirms FY26 CapEx view $110M.